Did A Special Protocol Assessment Actually Hurt Debiovision’s Sanvar?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs Advisory Committee concludes that flaws in the trial designed with FDA made it impossible to determine the efficacy of the drug for acute bleeding resulting from portal hypertension.